SA
Log In
JUBLPHARMA.NS
OverviewIntelligenceChart

No data available

Next earnings: May 22, 2026
Signal
Leaning Bearish1!
Price
1→
Move→+0.39%Quiet session
Volume
1→
Volume↓0.4× avgLight volume
Technical
1→
Trend↑Rally vs TrendAbove 50D, below 200D
PRICE
Prev Close
926.85
Open
924.50
Day Range920.10 – 935.50
920.10
935.50
52W Range786.05 – 1,248.00
786.05
1,248.00
31% of range
VOLUME & SIZE
Avg Volume
167.3K
Float
158.4M
FUNDAMENTALS
P/E Ratio
34.2x
EPS (TTM)
$27.24
Div Yield
No dividend
Quick Read
Earnings in 19d · May 22
Trend
RALLY
Price above SMA50, below SMA200
Momentum
BULLISH
price above key MAs · revenue +12% YoY
Valuation
EXPENSIVE
P/E 34x vs ~20x sector
Health
MODERATE
CR 1.7 · FCF negative
Bullish
Key MetricsTTM
Market Cap$147.38B
Revenue TTM$79.18B
Net Income TTM$4.33B
Free Cash Flow-$3.71B
Gross Margin45.1%
Net Margin5.5%
Operating Margin19.1%
Return on Equity6.9%
Return on Assets3.2%
Debt / Equity0.44
Current Ratio1.66
EPS TTM$27.32
Alpha SignalsView Intelligence →

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
2 strong2 watch2 concern
49/100
Liquidity
1.66Watch
Leverage
0.44Strong
Coverage
7.3xStrong
ROE
6.9%Concern
ROIC
8.6%Watch
Cash
$10.9BConcern
Analyst Coverage

No analyst coverage available for this stock.

Stock Health
Composite Score
3 of 6 signals bullish
6/10
Trend
●
Trend StateRally (above SMA50, lagging SMA200)
✓
●
Above SMA 50$870.31 (+6.9%)
✓
●
Above SMA 200$1023.54 (-9.1%)
✗
Technicals
●
MA AlignmentDeath Cross (50D vs 200D -15.0%)
✗
Fundamentals
●
Last EarningsMissed estimates
✗
●
LiquidityCurrent Ratio 1.66 — healthy liquidity
✓
Upcoming Events
EEarnings Report · After CloseMay 4, 2026
Tomorrow
DEx-Dividend DateJul 31, 2026
In 89 days
Research
Fundamentals→Financials→Analysts→Earnings→Growth→Key Metrics→Technical Analysis→Intelligence→
Technicals
Market Position
Price Levels
52W High
$1,248+34.1%
SMA 200
$1,024+10.0%
Current
$930.5
SMA 50
$870.3-6.5%
52W Low
$786.0-15.5%
52-Week RangeMid-range
$786.031th %ile$1,248
Earnings & Analysts

ANALYST ESTIMATES

Consensus of 2 analysts
Full estimates →
Analyst revisions:EPS↑ Revised UpRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$72.3B
$72.3B–$72.3B
—$36.53—
±24%
Low2
FY2026(current)
$81.1B
$80.6B–$81.5B
▲ +12.1%$34.38▼ -5.9%
±3%
Low2
FY2027
$91.3B
$89.3B–$93.2B
▲ +12.6%$45.25▲ +31.6%
±5%
Low2
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryJUBLPHARMA.NS
Last 8Q
+4.2%avg beat
Beat 6 of 8 quartersMissed 2↓ Estimates falling
+9%
Q4'23
-31%
Q3'24
+45%
Q4'24
+20%
Q1'25
+15%
Q2'25
+2%
Q3'25
+14%
Q4'25
-39%
Q1'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
Financials
Dividends0.54% yield
+33.9% avg annual growth
Annual Yield0.54%
Annual Div.$5.0000
Est. Annual / Share$5.00
FrequencyAnnual
Q3'18
Q3'19
Q1'20
Q3'21
Q3'22
Q3'23
Q3'24
Q3'25

Dividend per payment — last 8 periods

News & Activity

JUBLPHARMA.NS News

20 articles · 4h ago

About

No company information available

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance